A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
"You need to understand that we're about to embark on the busiest week of the year for industrial earnings," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Boston Federal Reserve President Eric Rosengren is lining up against an apparent push to cut interest rates, telling CNBC in an interview Friday that the central bank can...The Fedread more
The MTA reported that the 1, 2, 3, 4, 5 and 6 trains are all facing delays due to a network communications issue impacting service in both directions, NBC New York reports.Transportationread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
US officials including Treasury Secretary Steven Mnuchin and White House economic adviser Larry Kudlow will host a meeting at the White House on Monday of semiconductor and...Technologyread more
Trump's constant berating of the Fed and its actions does not influence the central bank's decisions, Boston Fed's Eric Rosengren says.The Fedread more
The lawsuits allege J&J's talc-based baby powder contained asbestos and caused ovarian and other cancers.Health and Scienceread more
Hundreds of thousands of doses a new Ebola vaccine could be ready to send to West Africa within the next three months, NewLink Genetics CEO Charles Link said Tuesday.
"We think by the end of the year we could have hundreds of thousands of doses, if the dose that's chosen is a moderate-size dose," he said. "It could be hundreds of thousands of doses, maybe more."
On CNBC's "Fast Money, " Link said that Phase 1 data of NewLink's vaccine is expected in December 2014.
The drug is currently being tested on 500 human volunteers in the United States, Britain, Germany, Switzerland, Mali, Gabon and Kenya. That Phase 1 data will determine the efficacy of the drug based on the human's antibody response to the vaccine.
"That data will be used to make a choice to then launch the larger scale trial (in West Africa) in a phased version in January of next year but it's a little hard to nail that date down today," said Link.